Employee Value Propositions (EVP) and attractive incentives are once again in focus as employers consider candidates who have potential rather than solely those who are an exact fit for the role, says recruiting experts Hays.
New data on UCBâ€™s anti-TNF biologic certolizumab pegol (Cimzia), disclosed this week in several poster presentations during the annual meeting of the American College of Rheumatology (ACR), show the treatment works well in rheumatoid arthritis (RA) patients irrespective of prior exposure to other biologics, and that results are sustained over 28 weeks.
Olwen Glynn Owen - Pharmiweb Field Reporter
Weâ€™re seeing increasing demand for pharma marketing solutions to be based on the iPad, and itâ€™s not hard to see why. The pace at which the industry continues its move away from paper-based detail aids seems to be increasing. But whatâ€™s interesting is that remote â€˜self-serviceâ€™ edetailing does not seem to be growing at the same rate. The predicted disintermediation of the traditional field sales model hasnâ€™t happened.
In the aftermath of last yearâ€™s inconclusive General Election â€” and the subsequent emergence of the Coalition Government â€” youâ€™d have been forgiven for thinking that â€˜deficit reductionâ€™ was the only buzzword in town.
Merck Serono, a division of Merck KGaA, Darmstadt Germany, in partnership with the European Head and Neck Society (EHNS), will convene an expert panel of physicians, who will issue a call-to-action that will focus on providing tailored information, advice and better support networks to head and neck cancer patients.
NICE is a world-renowned, independent organisation responsible for providing national recommendations on the use of new and existing medicines and treatments within the NHS, through the Technology Appraisal Programme. The Scientific Advice Programme provides not-for-profit chargeable consulting services to companies who have products in development that may be referred for future evaluation by NICE.
New drug formulations, biological agents, combination therapies and the latest pharmaceutical developments designed to improve outcomes in patients with a wide range of cancers were highlighted at EMCC 2001. Here are just a few of the highlights:
Science is always at its most exciting when it looks to the far horizons. And the unavoidably controversial yet incredibly promising area of stem cell science provides arguably one of the most apt examples.
Esther Dyson the Great Dame of Silicon Valley, at times matriarch to Bill Gates and many other lads on the innovative circuit, wrote a harsh column August 26th on GPS CNN on ICANN gTLD. I like and respect Esther especially her technical background, we have shared the podium, but as this topic deals with the centrality of global corporate nomenclature it demands an authoritative analysis and I feel itâ€™s my responsibility to clarify and taken the liberty to address her entire piece item by item.
For recent graduates from science, medicine, or mathematics programs, applying for work in the ever-expanding pharmaceutical industry can be an intelligent choice for both career and financial stability. Depending on the industry upon which you choose to focus, the rules and expectations during the interview process can vary.
Almost irrespective of the country you live in, the increasing costs of healthcare are unavoidable. For governments, the stresses are particularly acute, as both aging populations and the increasing cost of treatments add financial pressures year on year. Yet as a new study by the Institute of Fiscal Studies (IFS) confirms, we should not underestimate the extent to which the shape of the state has already changed.
Max Golby - PharmiWeb Field Reporter
At a moment when the national discourse on international aid is grounded in pessimism, David Cameronâ€™s pledge to commit Â£814m to help vaccinate the worldâ€™s poorest children provides an necessary reminder of what international aid really can achieve.
Certolizumab pegol (Cimzia Â®) delivered rapid and consistent improvements in a broad range of rheumatoid arthritis (RA) patients after 12 weeks of treatment regardless of whether or not they had received prior TNF inhibitors or whether or not they were receiving concomitant DMARDs, concluded the latest analysis of the Phase III b REALISTIC trial presented at the European League Against Rheumatism (EULAR) meeting in London, May 25-28 (abstract FRI021).
Both drugs are protease inhibitors (PIs) and are designed to block an enzyme that helps the hepatitis C virus replicate. Hepatitis C is a liver disease caused by infection with the hepatitis C virus, which is transmitted through contaminated blood. The infection can cause liver failure and liver cancer.
Rhonda Siddall-Freelance Medical Journalist and Writer
Brand managers and marketing leads are always striving to gain that first step of engagement, particularly in our world of pharmaceutical manufacturing. And with good reason. Customer engagement leads to improved understanding, which drives loyalty and ultimately improved health.
Eric Boothe, Director Business Developmentâ€”Life Sciences
Since the very dawn of Western capitalism, competition has been synonymous with success. Indeed, in accounting for the past 500 years of Western ascendancy in the world, Professor Niall Ferguson of Harvard University points to six â€˜killer appsâ€™. The first of these, unsurprisingly, is competition
Earlier this month the UK drugs giant GlaxoSmithKline announced a groundbreaking and progressive new scheme for graduates, whereby from 2012 the company will offer to reimburse in full the university tuition fees of the entirety its future graduate intake.
After six months of sometimes lively pursuit, the French pharmaceutical group, Sanofi-aventis, has agreed a deal to pay $20.1bn in cash for U.S. biotech firm Genzyme Corp after Sanofi made an increased offer of $74 per share.
Max Golby - PharmiWeb Field Reporter
Social networking sites such as Facebook, Linkedin and Twitter are all the rage â€“ thereâ€™s no escaping them, theyâ€™re everywhere â€“ even in the workplace, and whether you like it or not, theyâ€™re not going away.
Catherine Gutsell, CK Group
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her